2023-2024 Regular Session • New York Legislature
A08130
Legislative Summary
Relates to the classification of the drug xylazine as a schedule I controlled substance, and to the criminal sale and possession of xylazine or preparations, compounds, mixtures or substances containing xylazine.
Demographic Impact
Overall analysis of equity impact
60% Bias
Medium ConfidenceView detailed demographic breakdown ↓Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
10/13/2023
referred to health
Assembly
1/3/2024
referred to health
Assembly
5/14/2024
held for consideration in health
Assembly
Roll Call Votes
Assembly Health Committee: Held for Consideration
5/14/2024
17
Yea
7
Nay
0
Not Voting
2
Absent
Result: PASSED
Status Information
Current Status
Introduced(10/13/2023)
Chamber
Assembly
Committee
Health(Assembly)
Sponsors
Republican: 22
Primary Sponsor
Joseph DeStefano
Republican
Co-Sponsors (21)
Eric Brown
Republican
Michael Novakhov
Republican
Joseph Angelino
Republican
Jacob Blumencranz
Republican
Jodi Giglio
Republican
Lester Chang
Republican
Scott Bendett
Republican
John Lemondes
Republican
Anil Beephan
Republican
Jeff Gallahan
Republican
Stephen Hawley
Republican
Michael Durso
Republican
David DiPietro
Republican
Matthew Simpson
Republican
Kenneth Blankenbush
Republican
Brian Miller
Republican
Scott Gray
Republican
Marjorie Byrnes
Republican
Brian Maher
Republican
John Mikulin
Republican
Keith Brown
Republican